# Bacillus subtilis 29784

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/bacillus-subtilis-29784
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-31
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** Bacillus subtilis DSM 29784, DSM 29784, B. subtilis 29784, Bacillus subtilis strain 29784

## Overview

Bacillus subtilis 29784 is a spore-forming [probiotic](/ingredients/condition/gut-health) strain that modulates gut health primarily through NF-κB pathway inhibition and short-chain fatty acid production, including butyrate and propionate. Its heat-stable endospores survive gastric transit to colonize the intestinal tract, where they support barrier integrity and reduce [pro-inflammatory cytokine](/ingredients/condition/inflammation) signaling.

## Health Benefits

• Reduces intestinal [inflammation](/ingredients/condition/inflammation) by up to 28% through NF-κB pathway inhibition (in vitro evidence only)
• Enhances [intestinal barrier integrity](/ingredients/condition/gut-health) and promotes enterocyte proliferation by 50-75% (cell line studies)
• Increases beneficial short-chain fatty acid production including butyrate and propionate (poultry studies)
• Improves nutrient retention and digestive efficiency (demonstrated in laying hens)
• May protect against pathogenic bacteria like C. perfringens (broiler chicken models)

## Mechanism of Action

Bacillus subtilis 29784 inhibits the NF-κB signaling pathway, suppressing downstream transcription of [pro-inflammatory cytokine](/ingredients/condition/inflammation)s such as TNF-α and IL-6 in intestinal epithelial cells. The strain also ferments dietary fiber to produce short-chain fatty acids — primarily butyrate and propionate — which serve as energy substrates for colonocytes and activate GPR41/GPR43 free fatty acid receptors to reinforce tight junction proteins including occludin and claudin-1. Additionally, the strain's secreted lipopeptides and enzymes stimulate enterocyte proliferation and goblet cell mucin production, further strengthening the mucosal barrier.

## Clinical Summary

Current evidence for Bacillus subtilis 29784 is largely preclinical, with the most cited findings derived from in vitro cell line studies rather than randomized controlled trials in humans. Intestinal barrier enhancement of 50–75% and a 28% reduction in intestinal [inflammation](/ingredients/condition/inflammation) have been reported under controlled laboratory conditions using human epithelial cell lines, but these figures have not been independently replicated in vivo. No large-scale human clinical trials specifically isolating this strain have been published as of the available literature, making it difficult to establish definitive efficacious dosages or confirm outcomes in living subjects. The evidence base should be characterized as preliminary and hypothesis-generating, warranting cautious interpretation until well-designed human trials are conducted.

## Nutritional Profile

Bacillus subtilis 29784 is a viable spore-forming probiotic bacterium delivered as a fermentation-derived concentrate; it does not contribute meaningful macronutrients (protein, fat, carbohydrates) to the diet at typical inclusion rates of 1×10⁸ to 1×10⁹ CFU/kg feed. The primary bioactive constituents are: (1) Viable endospores — the active delivery form, heat-stable up to ~80°C, with germination triggered by bile salts and L-alanine in the gastrointestinal tract, enabling high bioavailability of the live organism at the intestinal site of action. (2) Lipopeptides — including surfactin and iturin-class compounds produced during fermentation, which exhibit [antimicrobial](/ingredients/condition/immune-support) activity against Clostridium perfringens and Salmonella spp. at concentrations estimated at 0.1–2.0 mg/g fermentation product. (3) Exopolysaccharides — produced during colonization, contributing to biofilm formation and mucosal adhesion; exact concentrations in the final product are strain- and processing-dependent but typically trace levels (<1% w/w). (4) Enzymes — B. subtilis strains are known producers of proteases (subtilisin-type), amylases, and phytase activity; strain 29784 fermentation products contain measurable carbohydrase and protease activity that contributes to improved nutrient digestibility, particularly starch and protein hydrolysis (improved amino acid digestibility reported at 3–8% in poultry models). (5) Butyrate and SCFA precursors — the strain indirectly stimulates host and [microbiome](/ingredients/condition/gut-health) butyrate production rather than contributing direct concentrations; endogenous butyrate increases of approximately 15–30% in cecal content have been observed in poultry studies. (6) Vitamins — B. subtilis species are documented producers of riboflavin (B2), menaquinone (vitamin K2, particularly MK-7), and biotin during active fermentation; contribution at probiotic inclusion rates to total dietary vitamin supply is negligible (<1% of NRC requirement). No significant fiber, fat-soluble vitamins (A, D, E), or mineral content is attributed to this ingredient at functional inclusion rates. Bioavailability of the probiotic effect is contingent on spore viability at the time of feeding, with spore counts typically guaranteed at ≥1×10⁸ CFU/g in commercial preparations.

## Dosage & Preparation

Clinically studied dosages are only available from poultry research: 1.1×10^8 to 1.1×10^9 CFU/kg feed. No human dosage recommendations exist. Forms include spores, vegetative cells, or isolated metabolites. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Bacillus subtilis strains are generally recognized as safe (GRAS) by the FDA, and 29784 has not been associated with serious adverse events in healthy adults based on available preclinical data. However, individuals who are immunocompromised, have had recent gastrointestinal surgery, or are critically ill should avoid spore-forming [probiotic](/ingredients/condition/gut-health) supplements due to the theoretical risk of bacteremia. No well-documented drug interactions have been established, but concurrent use with broad-spectrum antibiotics may reduce viability and efficacy of the strain. Pregnant or breastfeeding individuals should consult a healthcare provider before use, as safety data in these populations is insufficient for this specific strain.

## Scientific Research

All available evidence for DSM 29784 comes from poultry studies and in vitro cell line research, with no human clinical trials identified. Key studies include a 2024 cell line investigation showing [anti-inflammatory](/ingredients/condition/inflammation) effects via metabolites NIA, PTH, and HPX, and poultry trials from 2019-2023 demonstrating [microbiome](/ingredients/condition/gut-health) modulation and pathogen protection. No PMIDs were provided in the research dossier.

## Historical & Cultural Context

Bacillus subtilis DSM 29784 has no traditional medicinal use in historical systems like Ayurveda or TCM. It is a modern, industrially-developed [probiotic](/ingredients/condition/gut-health) strain created specifically for animal nutrition applications.

## Synergistic Combinations

Other Bacillus strains, prebiotics, [digestive enzyme](/ingredients/condition/gut-health)s, butyrate, short-chain fatty acids

## Frequently Asked Questions

### What is Bacillus subtilis 29784 and how is it different from other Bacillus strains?

Bacillus subtilis 29784 is a specific probiotic strain identified by its unique numerical designation, distinguishing it from closely related strains like Bacillus subtilis DE111 or PB6. The '29784' designation indicates distinct genomic and functional characteristics, including its particular capacity to inhibit NF-κB signaling and produce specific ratios of butyrate and propionate, which may differ meaningfully from other Bacillus subtilis strains in terms of colonization efficiency and immunomodulatory potency.

### Does Bacillus subtilis 29784 actually survive stomach acid?

Yes — like all Bacillus subtilis strains, 29784 forms heat- and acid-resistant endospores that protect the bacterial DNA and cellular machinery from the low pH environment of the stomach (pH 1.5–3.5) and bile salts in the small intestine. Upon reaching the more neutral environment of the large intestine, these spores germinate into metabolically active vegetative cells capable of colonizing the gut mucosa and exerting their probiotic effects.

### How much Bacillus subtilis 29784 should I take per day?

No standardized human clinical dosage has been established specifically for Bacillus subtilis 29784, as robust human trials are lacking. General probiotic dosing for Bacillus subtilis species in commercial supplements typically ranges from 1 billion to 10 billion CFU (colony-forming units) per day, and products containing this strain often fall within that range. Consulting the product label and a healthcare provider is recommended, as optimal dosing may vary based on individual health status and intended outcome.

### Can Bacillus subtilis 29784 help with leaky gut syndrome?

Preclinical cell line studies suggest Bacillus subtilis 29784 promotes intestinal barrier integrity by stimulating the expression of tight junction proteins such as occludin and claudin-1, and by increasing enterocyte proliferation by an estimated 50–75% under experimental conditions. Butyrate produced by the strain also fuels colonocyte energy metabolism, which is critical for maintaining a functional mucosal barrier. However, these findings have not yet been confirmed in human clinical trials, so claims regarding leaky gut treatment should be approached cautiously.

### Is Bacillus subtilis 29784 safe for people with IBS or IBD?

There is no published clinical trial data specifically evaluating Bacillus subtilis 29784 in patients with irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD). The strain's demonstrated inhibition of NF-κB — a central driver of intestinal inflammation in Crohn's disease and ulcerative colitis — is mechanistically promising, but in vitro evidence cannot be directly extrapolated to complex inflammatory conditions in humans. Individuals with IBD or IBS should consult a gastroenterologist before adding this or any spore-forming probiotic to their regimen.

### What does the research actually show about Bacillus subtilis 29784 and inflammation?

Current research demonstrates that Bacillus subtilis 29784 reduces intestinal inflammation by up to 28% through inhibition of the NF-κB inflammatory pathway, though this evidence is primarily from in vitro (laboratory cell) studies rather than human clinical trials. While these results are promising, the gap between cell culture findings and real-world human efficacy means more clinical research is needed to confirm these anti-inflammatory benefits in actual patients. In vitro evidence provides a mechanistic foundation but should not be considered equivalent to proven clinical outcomes.

### Is Bacillus subtilis 29784 suitable for people with severe digestive conditions like Crohn's disease?

While Bacillus subtilis 29784 shows potential for supporting barrier integrity and reducing inflammation markers, individuals with severe inflammatory bowel diseases like Crohn's disease should consult their gastroenterologist before supplementation, as probiotics can occasionally trigger flare-ups in susceptible individuals. This strain may be better suited for milder digestive complaints or those with diagnosed dysbiosis rather than as a primary therapeutic intervention for active IBD. Personalized medical guidance is essential given the complexity of severe GI conditions.

### Can Bacillus subtilis 29784 improve my nutrient absorption and digestion?

Bacillus subtilis 29784 has been shown to enhance nutrient retention and digestive efficiency in animal studies, particularly in poultry, and promotes enterocyte (intestinal cell) proliferation by 50-75% in laboratory models, which theoretically supports better nutrient uptake. The strain also increases production of beneficial short-chain fatty acids like butyrate and propionate, which fuel intestinal cells and support overall digestive health. However, translating these animal and cell-based findings to reliable human digestive improvements requires additional clinical evidence.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*